Replies to post #203617 on Biotech Values

[Jonathan Robinson]

Idiotic things out there.

[DewDiligence]

PTLA resubmits BLA for AndexXa (FXa antidote):

https://globenewswire.com/news-release/2017/08/03/1072296/0/en/Portola-Pharmaceuticals-Announces-Resubmission-of-Biologics-License-Application-for-AndexXa-Andexanet-Alfa.html

The resubmission includes supplemental information primarily related to manufacturing, as requested by the FDA in a complete response letter (CRL) issued to Portola in August 2016.

PTLA management seems to have matured since the embarrassing performance following the AndexXa CRL in 2016 (#msg-124624757).